Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|June 17, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-01-2015
- Volume 11
- Issue 7
Catalent expands packaging capabilities in Singapore
Author(s)Pharmaceutical Technology Editors
Catalent’s Singapore facility is awarded GMP certification.
Advertisement
Catalent announced on June 16 that it has expanded its Singapore facility to provide secondary packaging and labeling capabilities. The site, which recently received GMP approval from the Health Science Authority, is now approved for GMP across all its activities, including secondary packaging, label printing, storage, distribution, returns and destruction management.
Catalent offers clinical supply systems and facilities in the United States, United Kingdom, Germany, Singapore and China, and a network of more than 60 audited depots. The company reports that it can handle a range of international compliance and distribution requirements, and reduce customer turnaround time.
Source:
Articles in this issue
over 11 years ago
SGS Completes New Labs at Shanghai Facilityover 11 years ago
American Airlines Cargo Opens Philadelphia Facilityover 11 years ago
Assay Testing Shifts to Outsourced Operationsover 11 years ago
New Ways Around Hazardous Reagent Chemistryover 11 years ago
Making Manufacturing Modernization Easierover 11 years ago
GS1 US Appoints Greg Bylo Vice-President of Healthcareover 11 years ago
EMVO Names Service Providers for FMD Projectover 11 years ago
Novasep Plans ADC Facility in Franceover 11 years ago
Pharmacy Associations Ask FDA to Delay Track-and-Trace RequirementsAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement